These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 6614941)

  • 1. [Sunrabin for injection].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1983 Sep; 10(9):2077-81. PubMed ID: 6614941
    [No Abstract]   [Full Text] [Related]  

  • 2. [The effect of N4-behenoyl-1-beta-D-arabinofuranosylcytosine on human erythrocytes].
    Moriguchi T; Kakita T; Nishimura T; Kubo A; Ueda T; Nakamura T; Sasada M; Uchino H
    Rinsho Ketsueki; 1987 Sep; 28(9):1568-75. PubMed ID: 3437519
    [No Abstract]   [Full Text] [Related]  

  • 3. [The effect of antileukemic drugs on superoxide (O2-) production by human neutrophils].
    Katoh M; Shirai T; Umeda M; Yamaguchi R; Kaneko H; Ishikawa I; Yamauchi M; Kojima N
    Rinsho Ketsueki; 1987 Nov; 28(11):1948-55. PubMed ID: 2833643
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacological disposition in mice of O 2 :2'-anhydro-1- -D-arabinosylcytosine 3'-phosphate, a potential antileukemic agent.
    Focke JH; Broussard WJ; Nagyvary J
    Biochem Pharmacol; 1973 Mar; 22(6):703-13. PubMed ID: 4693492
    [No Abstract]   [Full Text] [Related]  

  • 5. Cytosine arabinoside (NSC-63878)--clinical brochure.
    Livingston RB; Carter SK
    Cancer Chemother Rep 3; 1968 Dec; 1(1):179-205. PubMed ID: 4989814
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in patients with acute leukemia.
    Ueda T; Nakamura T; Ando S; Kagawa D; Sasada M; Uchino H; Johno I; Akiyama Y
    Cancer Res; 1983 Jul; 43(7):3412-6. PubMed ID: 6850647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro assessment of drug sensitivity in acute nonlymphocytic leukemia.
    Preisler HD; Raza A
    Recent Results Cancer Res; 1984; 94():102-15. PubMed ID: 6593774
    [No Abstract]   [Full Text] [Related]  

  • 8. [Strategy of chemotherapy of a patient with acute leukemia based on the mechanism of action of drugs].
    Uchida M; Ueda T; Nakamura T
    Rinsho Ketsueki; 1986 Aug; 27(8):1445-53. PubMed ID: 3795516
    [No Abstract]   [Full Text] [Related]  

  • 9. Cytotoxicity of 2'-fluoro-5-iodo-1-beta-D-arabinofuranosylcytosine and its relationship to deoxycytidine deaminase.
    Cheng YC; Tan RS; Ruth JL; Dutschman G
    Biochem Pharmacol; 1983 Feb; 32(4):726-9. PubMed ID: 6830635
    [No Abstract]   [Full Text] [Related]  

  • 10. Experimental study on antitumor activity and pharmacokinetics of cytosine arabinoside, cyclocytidine and BH-AC.
    Takenaka T; Kimura K
    Nihon Ketsueki Gakkai Zasshi; 1984 Jul; 47(4):938-49. PubMed ID: 6209907
    [No Abstract]   [Full Text] [Related]  

  • 11. Determinants in chemosensitivity of oncogene-transformed NIH3T3 cells to 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine.
    Zhang M; Endo Y; Sasaki T
    Int J Oncol; 1999 Mar; 14(3):543-9. PubMed ID: 10024689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the conjugate between N4-(4-carboxybutyryl)-1-beta-D-arabinofuranosylcytosine and chitosan as a macromolecular prodrug of 1-beta-D-arabinofuranosylcytosine.
    Ichikawa H; Onishi H; Takahata T; Machida Y; Nagai T
    Drug Des Discov; 1993; 10(4):343-53. PubMed ID: 8148473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose cytarabine in acute leukemia: toxicity and pharmacokinetics.
    Pommier Y; Pochat L; Marie JP; Zittoun RA
    Cancer Treat Rep; 1983 Apr; 67(4):371-3. PubMed ID: 6850654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological disposition and metabolic fate of 2'-fluoro-5-iodo-1-beta-D-arabinofuranosylcytosine in mice and rats.
    Chou TC; Feinberg A; Grant AJ; Vidal P; Reichman U; Watanabe KA; Fox JJ; Philips FS
    Cancer Res; 1981 Sep; 41(9 Pt 1):3336-42. PubMed ID: 7260900
    [No Abstract]   [Full Text] [Related]  

  • 15. [Damage of vascular endothelium in the treatment of acute leukemia: in vitro study].
    Romanov IuA; Chervontseva AM; Savchenko VG
    Ter Arkh; 2004; 76(7):34-40. PubMed ID: 15379125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.
    Beran M; Jeha S; O'Brien S; Estey E; Vitek L; Zurlo MG; Rios MB; Keating M; Kantarjian H
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2377-84. PubMed ID: 9815637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular pharmacodynamics of anticancer drugs.
    Plunkett W; Gandhi V
    Semin Oncol; 1993 Feb; 20(1):50-63. PubMed ID: 8475410
    [No Abstract]   [Full Text] [Related]  

  • 18. Informal discussion: experimental basis for the chemical eradication of leukemia.
    Frei E
    Cancer Res; 1967 Dec; 27(12):2656-7. PubMed ID: 6082303
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of acute leukemia with newly synthesized N4-behenoyl-l-beta-D-arabinofuranosylcytosine (BH-AC) (author's transl)].
    Sueyama H; Oguro M; Takagi T
    Rinsho Ketsueki; 1981 Jul; 22(7):1109-15. PubMed ID: 7328768
    [No Abstract]   [Full Text] [Related]  

  • 20. Mechanism of action of cyclocytidine in leukemic cells.
    Nakamura T; Wakisaka G
    Bibl Haematol; 1975; (40):755-6. PubMed ID: 1164408
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.